deltatrials
Completed OBSERVATIONAL NCT04747496

Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China (ETNA-AF-CHINA)

Real-world Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation in China

Sponsor: Daiichi Sankyo

Conditions Non-valvular Atrial Fibrillation
Interventions Edoxaban
Updated 19 times since 2021 Last updated: Jan 7, 2025 Started: Feb 26, 2021 Primary completion: Nov 27, 2024 Completion: Nov 27, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04747496, this observational or N/A phase trial focuses on Non-valvular Atrial Fibrillation and remains completed. Sponsored by Daiichi Sankyo, it has been updated 19 times since 2021, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Aug 2023 · 11 months · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Mar 2024 · 5 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Feb 2025 · 3 months · monthly snapshot~Feb 2025 – ~Oct 2025 · 8 months · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

19 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed

  2. Feb 2025 — Oct 2025 [monthly]

    Completed

    Status: Active Not Recruiting → Completed

  3. Nov 2024 — Feb 2025 [monthly]

    Active Not Recruiting

  4. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting

▶ Show 14 earlier versions

  1. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting

  2. Oct 2023 — Mar 2024 [monthly]

    Active Not Recruiting

  3. Aug 2023 — Oct 2023 [monthly]

    Active Not Recruiting

    Status: Recruiting → Active Not Recruiting

  4. Sep 2022 — Aug 2023 [monthly]

    Recruiting

  5. Jul 2022 — Sep 2022 [monthly]

    Recruiting

  6. May 2022 — Jul 2022 [monthly]

    Recruiting

  7. Feb 2022 — May 2022 [monthly]

    Recruiting

  8. Jan 2022 — Feb 2022 [monthly]

    Recruiting

  9. Dec 2021 — Jan 2022 [monthly]

    Recruiting

  10. Oct 2021 — Dec 2021 [monthly]

    Recruiting

  11. Sep 2021 — Oct 2021 [monthly]

    Recruiting

  12. Jun 2021 — Sep 2021 [monthly]

    Recruiting

  13. May 2021 — Jun 2021 [monthly]

    Recruiting

    Status: Not Yet Recruiting → Recruiting

  14. Mar 2021 — May 2021 [monthly]

    Not Yet Recruiting

    First recorded

Feb 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Daiichi Sankyo
  • Daiichi Sankyo Co., Ltd.
Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Changsha, China , Changzhi, China , Changzhou, China , Chengdu, China , Chongqing, China , Dalian, China , Guangzhou, China , Hangzhou, China and 28 more locations